Kura Oncology (KURA)
(Delayed Data from NSDQ)
$18.97 USD
-0.15 (-0.78%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $18.95 -0.02 (-0.11%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 81 - 100 ( 263 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Registration-Directed Phase 2 KOMET-001; Combination Studies Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
FTI Portfolio Expands With a Novel Next-Gen Candidate; KO-2806?s Phase 1 Initiation in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 122122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Ziftomenib Steps It Up at ASH With Nice KOMET-001 Update; First Pivotal in 1Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 121122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Robust Ph 1b Expansion Data Sets Stage for Comprehensive Development Plan
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 12122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 112122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 111122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Ziftomenib ASH Abstract Data Out; Comprehensive Update Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Strategic Equity Raise Hints at BD Promise; Oral Preso at ASH for Phase 1/2 KOMET-001
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J